Skip to content

Study · Non-randomized trial · 2006

7 results

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

Ionescu M, Frohman LA

The Journal of clinical endocrinology and metabolism3 Oct 2006Cited by 25 (Europe PMC)

PMID17018654 (opens in a new tab)DOI10.1210/jc.2006-1702 (opens in a new tab)PepBankPUB-17018654
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy men, a single CJC‑1295 injection increased overall mean GH levels by 46% one week later.

    In plain wordsIn healthy men, one CJC‑1295 injection raised average growth hormone levels by 46% a week later.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    IncreaseMean GH secretion
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    60 or 90 microg/kg · injectionAs given in this study (human).

    Measurements

    Mean GH level increase
    46%
    1 wk after injection

    Source sentences

    Summary
    overall increase in GH secretion (mean GH levels, 46%; P < 0.01
    1 context sentence
    Summary · context
    GH pulsatility was assessed by 20-min blood sampling during an overnight 12-h period in healthy 20- to 40-yr-old men before and 1 wk after injection of either 60 or 90 microg/kg CJC-1295.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy men, a single CJC‑1295 injection markedly increased basal (trough) GH levels 7.5-fold one week later.

    In plain wordsIn healthy men, one CJC‑1295 injection raised the lowest growth hormone levels between pulses 7.5-fold a week later.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    IncreaseBasal (trough) GH level
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    60 or 90 microg/kg · injectionAs given in this study (human).

    Measurements

    Basal GH fold increase
    7.5 fold
    1 wk after injection

    Source sentences

    Summary
    basal (trough) GH levels were markedly increased (7.5-fold; P < 0.0001
    1 context sentence
    Summary · context
    GH pulsatility was assessed by 20-min blood sampling during an overnight 12-h period in healthy 20- to 40-yr-old men before and 1 wk after injection of either 60 or 90 microg/kg CJC-1295.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy men, a single CJC‑1295 injection increased IGF-I levels by 45% one week later.

    In plain wordsIn healthy men, one CJC‑1295 injection raised IGF-I levels by 45% a week later.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    IncreaseIGF-I level
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    60 or 90 microg/kg · injectionAs given in this study (human).

    Measurements

    IGF-I level increase
    45%
    1 wk after injection

    Source sentences

    Summary
    IGF-I levels (45%; P < 0.001)
    1 context sentence
    Summary · context
    GH pulsatility was assessed by 20-min blood sampling during an overnight 12-h period in healthy 20- to 40-yr-old men before and 1 wk after injection of either 60 or 90 microg/kg CJC-1295.
  4. 04HumanNon-randomized trialMechanism

    In healthy men, the frequency of GH secretory pulses was unaltered after CJC‑1295.

    In plain wordsIn healthy men, CJC‑1295 did not change how often growth hormone pulses occurred.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    No significant changeGH secretory pulse frequency
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    60 or 90 microg/kg · injectionAs given in this study (human).

    Source sentences

    Summary
    The frequency and magnitude of GH secretory pulses were unaltered.
    1 context sentence
    Summary · context
    GH pulsatility was assessed by 20-min blood sampling during an overnight 12-h period in healthy 20- to 40-yr-old men before and 1 wk after injection of either 60 or 90 microg/kg CJC-1295.
  5. 05HumanNon-randomized trialMechanism

    In healthy men, the magnitude of GH secretory pulses was unaltered after CJC‑1295.

    In plain wordsIn healthy men, CJC‑1295 did not change the size of growth hormone pulses.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    No significant changeGH secretory pulse magnitude
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    60 or 90 microg/kg · injectionAs given in this study (human).

    Source sentences

    Summary
    The frequency and magnitude of GH secretory pulses were unaltered.
    1 context sentence
    Summary · context
    GH pulsatility was assessed by 20-min blood sampling during an overnight 12-h period in healthy 20- to 40-yr-old men before and 1 wk after injection of either 60 or 90 microg/kg CJC-1295.
  6. 06HumanNon-randomized trialEfficacy outcome

    In healthy men, responses to the 60 and 90 microg/kg CJC‑1295 doses did not differ significantly.

    In plain wordsIn healthy men, the 60 and 90 microg/kg doses of CJC‑1295 gave no significant difference in response.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    No significant changeDose comparison, 60 versus 90 microg/kg
    Study

    n: not reported in source

    Comparator
    60 versus 90 microg/kg
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    60 or 90 microg/kg · injectionAs given in this study (human).

    Source sentences

    Summary
    No significant differences were observed between the responses to the two drug doses.
    1 context sentence
    Summary · context
    GH pulsatility was assessed by 20-min blood sampling during an overnight 12-h period in healthy 20- to 40-yr-old men before and 1 wk after injection of either 60 or 90 microg/kg CJC-1295.
  7. 07HumanNon-randomized trialMechanism

    In healthy men given CJC‑1295, the IGF-I increases did not correlate with any parameter of GH secretion.

    In plain wordsIn healthy men given CJC‑1295, the rise in IGF-I did not track with any measured feature of growth hormone secretion.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    No significant changeCorrelation of IGF-I increase with GH secretion parameters
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    60 or 90 microg/kg · injectionAs given in this study (human).

    Source sentences

    Summary
    The IGF-I increases did not correlate with any parameters of GH secretion.
    1 context sentence
    Summary · context
    GH pulsatility was assessed by 20-min blood sampling during an overnight 12-h period in healthy 20- to 40-yr-old men before and 1 wk after injection of either 60 or 90 microg/kg CJC-1295.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.